Indobufen

Cat. No.: HY-18763

CAS No.: 63610-08-2

Molecular Formula: $C_{18}H_{17}NO_3$

Molecular Weight: 295.33

Target: COX

Pathway: Immunology/Inflammation

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (846.51 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.3860 mL	16.9302 mL	33.8604 mL
	5 mM	0.6772 mL	3.3860 mL	6.7721 mL
	10 mM	0.3386 mL	1.6930 mL	3.3860 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (7.04 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (7.04 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A_2 (TxA_2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].

IC_{50} & Target

COX

In Vitro

Indobufen does not affect both Cox-1 and Cox-2 protein, whereas Indobufen reduces TxB_2 levels. Indobufen inhibits TxA_2 but not PGE_2 synthesis in LPS-stimulated monocytes. Indobufen reduces the extent of ERK1/2 phosphorylation, whereas the levels of phosphorylated p38 are unaltered[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Eligini S, et al. Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism. Cardiovasc Res. 2006 Jan;69(1):218-26.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA